Unlocking New Treatment Strategies for Chronic Myelomonocytic Leukemia: Pacritinib and Azacitidine in Clinical Trial
In today’s episode, Dr. Douglas Tremblay, from Mount Sinai in New York City, explains the basics of chronic myelomonocytic leukemia (CMML) and breaks down what makes it such a tough disease to treat. He then walks our audience through the current treatment options for CMML and ends by sharing the exciting new research he’s doing to change how CMML is treated.
Dr. Tremblay’s study on pacritinib in combination with azacitidine is enrolling now! If you live in or near New York City and want to learn more about the study to see if it might be right for you, you can reach out to him directly at: douglas.tremblay@mssm.edu
Thanks for listening!
Mary introduces our speaker Dr. Douglas Tremblay
Dr. Tremblay explains CMML basics, treatments, and his research on pacritinib with azacitidine, aiming to improve CMML care.
Mary Arnett
Mary joined HealthTree in 2022 as a part of HealthTree's team to help expand into all blood cancers. She now works as HealthTree's Volunteer & Community Outreach Manager, helping to engage and involve community members in HealthTree's mission. When she isn't working, she loves being the fun aunt to her 13 nieces and nephews, attending concerts, experimenting with new recipes in the kitchen, and traveling to explore new cities.
Douglas Tremblay, MD
Dr. Tremblay has led multi-institutional research efforts in myeloproliferative neoplasms and is actively involved in both investigator-initiated and industry sponsored early and late phase clinical trials in myeloid neoplasms. Dr. Tremblay specializes in hematologic malignancies including acute myeloid leukemia, myeloproliferative neoplasms and myelodysplastic syndromes.